title: Loss of translation elongation factor (eEF1A2) expression in vivo differentiates between Wallerian degeneration and dying-back neuronal pathology.
abstract: Wallerian degeneration and dying-back pathology are two well-known cellular pathways capable of regulating the breakdown and loss of axonal and synaptic compartments of neurons in vivo. However, the underlying mechanisms and molecular triggers of these pathways remain elusive. Here, we show that loss of translation elongation factor eEF1A2 expression in lower motor neurons and skeletal muscle fibres in homozygous Wasted mice triggered a dying-back neuropathy. Synaptic loss at the neuromuscular junction occurred in advance of axonal pathology and by a mechanism morphologically distinct from Wallerian degeneration. Dying-back pathology in Wasted mice was accompanied by reduced expression levels of the zinc finger protein ZPR1, as found in other dying-back neuropathies such as spinal muscular atrophy. Surprisingly, experimental nerve lesion revealed that Wallerian degeneration was significantly delayed in homozygous Wasted mice; morphological assessment revealed that approximately 80% of neuromuscular junctions in deep lumbrical muscles at 24 h and approximately 50% at 48 h had retained motor nerve terminals following tibial nerve lesion. This was in contrast to wild-type and heterozygous Wasted mice where < 5% of neuromuscular junctions had retained motor nerve terminals at 24 h post-lesion. These data show that eEF1A2 expression is required to prevent the initiation of dying-back pathology at the neuromuscular junction in vivo. In contrast, loss of eEF1A2 expression significantly inhibited the initiation and progression of Wallerian degeneration in vivo. We conclude that loss of eEF1A2 expression distinguishes mechanisms underlying dying-back pathology from those responsible for Wallerian degeneration in vivo and suggest that eEF1A2-dependent cascades may provide novel molecular targets to manipulate neurodegenerative pathways in lower motor neurons.
authors.affiliation: Centre for Integrative Physiology, College of Medicine, and Veterinary Medicine, University of Edinburgh, Edinburgh, EH8 9XD, UK.
authors.forename: Lyndsay M
authors.initials: LM
authors.lastname: Murray
authors.forename: Derek
authors.initials: D
authors.lastname: Thomson
authors.forename: Annalijn
authors.initials: A
authors.lastname: Conklin
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Wishart
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Gillingwater
mesh_terms: D000818:Animals; D001369:Axons / Q000473:pathology; D015153:Blotting, Western / Q000379:methods; D017353:Gene Deletion; D006579:Heterozygote; D007150:Immunohistochemistry; D051379:Mice; D008817:Mice, Mutant Strains; D008856:Microscopy, Fluorescence; D009046:Motor Neurons / Q000473:pathology; D018485:Muscle Fibers, Skeletal / Q000473:pathology; D009410:Nerve Degeneration / Q000235:genetics*; D009469:Neuromuscular Junction / Q000473:pathology*; D020648:Peptide Elongation Factor 1 / Q000235:genetics*; D013569:Synapses / Q000473:pathology; D014855:Wallerian Degeneration / Q000235:genetics* / Q000473:pathology
chemical_list: C503235:Eef1a2 protein, mouse; D020648:Peptide Elongation Factor 1